{
  "query": "VYGR",
  "resolved": {
    "ticker": "VYGR",
    "cik": "0001640266",
    "title": "Voyager Therapeutics, Inc."
  },
  "signals": [
    {
      "type": "trial_to_filing",
      "headline": "Voyager Therapeutics, Inc. (VYGR) — PHASE2 primary completion 21 days ago (readout window)",
      "entity": "Voyager Therapeutics",
      "ticker": "VYGR",
      "cik": "0001640266",
      "tickerConfidence": 0.95,
      "upstream": {
        "event": "Clinical trial status (PHASE2)",
        "detail": "VY7523-102: Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study in Participants With Early Alzheimer's Disease",
        "nctId": "NCT06874621",
        "date": "2026-10-13"
      },
      "observed": {
        "event": "primary completion 21 days ago (readout window)",
        "nctId": "NCT06874621"
      },
      "predicted": {
        "event": "SEC 8-K / press release on Phase 3 initiation",
        "leadTime": "18-36 mo",
        "baseRate": 0.29,
        "note": "Reg FD requires prompt disclosure of material clinical results."
      },
      "leadTime": "Phase-transition base rate 28% (Wong/Siah/Lo 2019)",
      "confidence": 0.55,
      "links": {
        "trial": "https://clinicaltrials.gov/study/NCT06874621",
        "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001640266&type=8-K"
      }
    },
    {
      "type": "trial_to_filing",
      "headline": "Voyager Therapeutics, Inc. (VYGR) — PHASE1 protocol updated 5 days ago",
      "entity": "Voyager Therapeutics",
      "ticker": "VYGR",
      "cik": "0001640266",
      "tickerConfidence": 0.95,
      "upstream": {
        "event": "Clinical trial status (PHASE1)",
        "detail": "An Open Label Dose Escalation Study of VY1706 in Participants With Early Alzheimer's Disease",
        "nctId": "NCT07764146",
        "date": "2029-04-28"
      },
      "observed": {
        "event": "protocol updated 5 days ago",
        "nctId": "NCT07764146"
      },
      "predicted": {
        "event": "SEC 8-K / press release on Phase 2 readout / advance",
        "leadTime": "12-24 mo",
        "baseRate": 0.52,
        "note": "Reg FD requires prompt disclosure of material clinical results."
      },
      "leadTime": "Phase-transition base rate 52% (Wong/Siah/Lo 2019)",
      "confidence": 0.35,
      "links": {
        "trial": "https://clinicaltrials.gov/study/NCT07764146",
        "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001640266&type=8-K"
      }
    }
  ],
  "recentFilings": {
    "name": "Voyager Therapeutics, Inc.",
    "sicDescription": "Biological Products, (No Diagnostic Substances)",
    "filings": [
      {
        "form": "8-K",
        "date": "2026-10-21",
        "accession": "0001193125-26-427224",
        "items": "5.02,9.01"
      },
      {
        "form": "8-K",
        "date": "2026-08-06",
        "accession": "0001640266-26-000007",
        "items": "2.02,9.01"
      },
      {
        "form": "8-K",
        "date": "2026-07-13",
        "accession": "0001104659-26-082906",
        "items": "8.01"
      },
      {
        "form": "8-K",
        "date": "2026-06-10",
        "accession": "0001104659-26-072324",
        "items": "5.03,5.07,9.01"
      },
      {
        "form": "8-K",
        "date": "2026-06-01",
        "accession": "0001104659-26-068591",
        "items": "8.01"
      }
    ]
  },
  "disclaimer": "Research/informational. NOT investment advice.",
  "generatedAt": "2026-11-03T09:00:20.748Z"
}